Navigation Links
Stem cell-based bioartificial tissues and organs
Date:2/18/2013

Surgeon Paolo Macchiarini has made his name by successfully transplanting bioengineered stem cell-based trachea, composed of both artificial and biological material. He now plans to use the technique to recreate more complex tissues, such as the oesophagus and diaphragm or organs such as the heart and lungs. He has also made an experimental attempt to regenerate brain in mice and rats. This is part of the news he will be presenting during his seminar at the scientific AAAS Annual Meeting in Boston.

In June 2011, media all over the world reported about a ground breaking transplant, where a patient received an artificial trachea covered in his own stem cells. The result was an artificial windpipe with biological functions. To date, five operations have been carried out using this technique.

"We learn something from each operation. This means we can develop and refine the technique. We are also evaluating how we can transfer our experiences to other fields, such as neurology. The aim is to make as much use of the body's own healing potential as we can", says Paolo Macchiarini, Professor of Regenerative Surgery at Karolinska Institutet, and responsible for the surgery.

At the AAAS Annual Meeting, he will talk about how he believes the technology can be used in the future. This will include:

  • The plan to operate on a 2 year-old girl in the USA in March. The girl was born without a trachea and has lived her entire life in intensive care, where she breathes through a tube placed in the oesophagus and connected directly to the lungs. Without a new trachea, she will never be able to leave the hospital. This will be the first time the procedure is conducted on a small child. It is also the first time the procedure will be conducted on an individual without a trachea - as previously, diseased organs have been replaced.

  • There are also plans to transplant the oesophagus, an organ that is more complex than a trach
    '/>"/>

Contact: Sabina Bossi
sabina.bossi@ki.se
46-706-146-066
Karolinska Institutet
Source:Eurekalert

Page: 1 2

Related biology news :

1. Novel aptamer boosts T cell-based immune response to therapeutic vaccines
2. New technique could make cell-based immune therapies for cancer safer and more effective
3. Discovery of reprogramming signature may help further stem cell-based regenerative medicine research
4. Scale-up of a temporary bioartificial liver support system described in BioResearch Open Access
5. New methods for quantifying antisense drug delivery to target cells and tissues
6. 3-D biomimetic scaffolds support regeneration of complex tissues from stem cells
7. Long-distance solute transport in trees improved by intercellular pathways in living woody tissues
8. Tiny probes shine brightly to reveal the location of targeted tissues
9. Researchers develop method to grow artificial tissues with embedded nanoscale sensors
10. Why do organisms build tissues they seemingly never use?
11. Penn researchers improve living tissues with 3-D printed vascular networks made from sugar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN JOSE, Calif. , Nov. 20, 2014 /PRNewswire/ ... a global leader in microcontroller (MCU) and touch technology ... digital temperature sensors with the widest V ... family delivers higher temperature accuracy and faster I 2 ... nonvolatile registers and serial EEPROM memory making them ideal ...
(Date:11/18/2014)... 2014   News Highlights: ... develop The Partners Data Lake, an agile data ... Lake will allow researcher and clinicians to explore ... the lives of patients , The Partners ... across the Partners system, breaking down physical barriers ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... This release is available in French . ... Generation Investment Management, the private bankers Lombard Odier Darier ... new chair at EPFL dedicated to sustainable development. The ... education between fundamental and social sciences in the environmental ...
... Berlin, 15 April 2008 -- European breast cancer specialists ... fight against breast cancer by bringing together world leaders ... European scientific meeting, IMPAKT (IMProving cAre and Knowledge ... to be held 7-9 May 2009 in Brussels, Belgium, ...
... well as cutting our fossil fuel emissions, planting new ... effectively can capitalise on natures ability to act as ... access journal Carbon Balance and Management shows that although ... problems, large-scale plantations could have a significant effect in ...
Cached Biology News:EPFL Research Day 2008, in the presence of Al Gore 2EPFL Research Day 2008, in the presence of Al Gore 3Improving care and knowledge in translational research to fight breast cancer 2Forests' long-term potential for carbon offsetting 2
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 The ... million in 2013, and is expected to grow ... 2019. , Browse through the TOC of the ... industry trends and segments, with help of various ... The global DNA Microarray market consists of instrument, ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4
... Innovative Formulation Available Without a ... Prescription Through Physicians, ... the,launch of PSORENT, a clinically proven, steroid-free, topical treatment ... efficacy against psoriasis symptoms, in a novel, aesthetically,advanced formulation ...
... is pleased to announce that they have acquired ... fully diluted basis. The cash consideration,will be used ... further develop,its technology., Molecular Vision is developing ... that will greatly extend the in-house tools,available to ...
... SOMERSET, N.J., Feb. 4 inVentiv Health, Inc.,(Nasdaq: ... Chief Executive Officer,and David Bassin, Chief Financial Officer, ... Healthcare Services Conference in New York City, which ... feature companies,spanning all sectors of healthcare, with management ...
Cached Biology Technology:NeoStrata(R) Announces the Launch of PSORENT(TM) Psoriasis Topical Treatment 2Acrongenomics Acquires Equity Stake in Molecular Vision 2Acrongenomics Acquires Equity Stake in Molecular Vision 3inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference 2